<DOC>
	<DOC>NCT02625974</DOC>
	<brief_summary>This study was designed to develop a better understanding of the efficacy, safety/tolerability, and pharmacokinetics (PK) (absorption, distribution, metabolism, and elimination) of nifurtimox in children with a diagnosis of Chagas' disease (Trypanosoma cruzi infection) using pediatric formulations.</brief_summary>
	<brief_title>Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease</brief_title>
	<detailed_description />
	<mesh_term>Chagas Disease</mesh_term>
	<mesh_term>Nifurtimox</mesh_term>
	<criteria>Male and female pediatric subjects aged 0 days to younger than 18 years Chagas' disease diagnosed/confirmed by: Subjects &lt; 8 months of age at randomization must demonstrate direct observation of Trypanosoma cruzi by concentration test Subjects â‰¥ 8 months to &lt; 18 years of age at randomization must demonstrate a positive conventional ELISA result for both of the following tests to confirm diagnosis: Recombinant ELISA Total purified antigen ELISA Females of childbearing potential (i.e., female subjects who have experienced menarche) and male subjects must agree to use adequate contraception if sexually active from the time of signing the informed consent/assent form until 3 months after the last study drug administration. Subjects aged 0 to 27 days who, at birth, were preterm (i.e., gestational age less than 37 weeks), weighed less than 2500 g, or had a maximum Apgar score &lt;7 at 5 minutes Subjects with any of the following conditions that is associated with Chagas' disease, such as: Known evidence of Chagas' diseaserelated cardiomyopathy/Chagas' heart disease Known evidence of Chagas' diseaserelated gastrointestinal dysfunction (e.g., megaoesophagus, megacolon, or both) or Chagas' digestive disease Clinically significant psychiatric disorder (e.g., moderate to severe depression, severe anxiety, or psychosis) or epilepsy Subjects with contraindications/warnings to nifurtimox administration, or with conditions that may increase the risk of the undesirable effects of nifurtimox, including: Hypersensitivity to nifurtimox or any hydantoin, or to any of the excipients Suspected or known porphyria Severe renal impairment Severe hepatic impairment History of brain injury, predisposition to seizures or epilepsy, psychiatric disease, or serious behavioral alteration Subjects who have had previous treatment with trypanocidal agents or an accepted indication for antiparasitic therapy (e.g., reactivation of Chagas' infection due to immunosuppression by several diseases or treatment with steroids) Subjects living in housing conditions where there is no active or effective vector control to T. cruzi reinfection as determined by Ministry of Health guidelines in each country</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>